New Product Development. Notwithstanding anything in this Agreement to the contrary, the transfer and assignment to Bioglan by the LLC of the Purchased Assets shall not prevent the LLC, IMX or Medicis from continuing to manufacture and sell other products included or expected to be included in their current line or to use other trademarks owned by the LLC, IMX or Medicis or restrict the rights of the LLC, IMX or Medicis to develop and sell new products using the same active ingredients contained in the Products, but using different formulations, or different presentations, and under different product trademarks.
Appears in 2 contracts
Sources: Asset Purchase Agreement (Medicis Pharmaceutical Corp), Asset Purchase Agreement (Imx Pharmaceuticals Inc)